Currently, the efficacy of combining the Menin inhibitor revumenib, venetoclax, and a hypomethylating agent is being investigated in children with relapsed/refractory AML in a phase I/II, investigator‐initiated trial (NCT05360160).166. Here, MEN1 is linked to acute myeloid leukemia.